Forte's Value Destruction Analysis

Significant Value Destruction Under Chair and CEO Dr. Wagner Forte has delivered negative total stockholder returns ("TSR") and significantly underperformed relevant indices over all relevant time horizons 20% 0% -20% -40% -60% -80% -100% 1-Year TSR 14.7% -13.9% Forte Biosciences -0.2% 3-Year TSR 1.5% -95.6% ■NASDAQ Biotechnology Index -3.8% TSR Since IPO Source: Bloomberg. TSR as of market close on May 24, 2023 (the day before Camac's preliminary proxy statement was filed with the SEC). 3.8% -94.8% S&P Pharmaceuticals Select Industry Index 0.7% Concerned Stockholders of Forte Biosciences 8

View entire presentation